HPV - tratamiento del hpv
Public Health workshop enhances programing of 26th International Papillomavirus Conference
MONTREAL,
Mar. 2, 2010 (Canada NewsWire Group) -- /CNW Telbec/ -- Public health
professionals are for the first time invited to the Public Health
Workshop, a bilingual preconference that will be held July 3 to 4,
2010, at the Palais des congrès de Montréal, as a
complement to the 26th International Papillomavirus Conference. The
initiative, proposed jointly by the Public Health Agency of Canada and
the Institut national de santé publique du
Québec, will highlight the many public health issues
connected with preventing human papillomavirus (HPV) and related
diseases and cancers.
Dr. Marc Steben,
Steering Committee co-chair, elaborates: "The Public Health Workshop
will meet a real need for skills development. We are committed to
making the training as interactive as possible, with a view to
exchanging information and building on the lessons learned, in addition
to the many solutions that have come from HPV-related experiences here
and elsewhere."
More info
HPV vaccine now available for boys
By QMI
Agency
Last
Updated: February 23, 2010 2:39pm
An
HPV vaccine that protects women from most varieties of genital warts
and cervical cancer, has been approved for use by boys and men in
Canada.
The
vaccine, Gardasil, has been approved for boys and men ages nine through
26, the same age range as its approval in girls and women. In 2007, the
federal government announced $300 million in funding to deliver
More info
HPV vaccine to prevent genital warts approved for males aged 9 to 26 in Canada
(CP)
– 19 hours ago
TORONTO
— The vaccine manufacturer Merck says Health Canada has
approved Gardasil for the prevention of genital warts caused by HPV
infection in boys and men aged nine to 26.
HPV,
or human papillomavirus, is the most common sexually transmitted
infection and can also cause anal cancer in men. Gardasil has already
been approved for females aged nine to 26 in Canada to prevent cervical
cancer and genital warts.
The
vaccine is designed to prevent infection by four of the most common
strains of the virus.
More info
Bill seeks more HPV coverage
By
Marissa Cumbers
New
legislation proposed in a Michigan Senate committee would require
health insurance providers to cover testing for human papillomavirus,
or HPV.
Insurance
providers would be required to cover the HPV test, which exposes a
virus that is linked to cervical cancer, under a two-bill package
sponsored by state Sen. Martha Scott, D-Highland Park.
“Women
are dying before their time because they can’t have this
test,” Scott said.
More info
Free and reduced HPV vaccine
By Myrriah Gossett
The Coastal Health
District will offer women aged 19-26 the full Human Papillomavirus
vaccine. The treatment was developed to help prevent cervical cancer
caused by HPV.
The vaccine is given
over a course of three doses. All three are required for the vaccine to
be fully effective. The series, which normally cost upwards of $160 per
dose, will only cost an administrative fee of $14. However, the Coastal
Health District has said that they will not turn away those who cannot
pay the fee.
More info
Cervical cancer vaccine, conference offer women hope
Tuesday,
02 March 2010 19:54 By Maya Prabhu
March could mark a
turning point in the fight against cervical cancer in Uganda.
In the context of the increasing international availability of a new
vaccine, government officials and NGOs involved in the struggle against
cervical cancer will launch a strategic plan to combat the disease.
Prevention
International: No Cervical Cancer brings care, training and equipment
to clinics and hospitals in 8 countries, screening and treating poor
women.
At the same time,
Mulago Hospital, Makerere University, and the organisation PATH will
begin joint research into new methods of screening for the illness.
Efforts also include a pilot vaccination distribution programme
currently taking place in two districts, which aims to gather
sufficient information to make possible a future national vaccination
strategy. Furthermore, the Uganda Cancer Institute will contribute to
plans for a comprehensive national policy on cancer.
More info
Screens, Vaccine for HPV Less Beneficial in Older Women
Rate of new infections declined with age, study
found
THURSDAY, Feb. 18 (HealthDay News) -- As women age, they receive fewer
benefits from frequent screening for human papillomavirus (HPV) and
vaccinations to prevent the virus, new research shows.
While infection with certain types of HPV can lead to cervical cancer,
there is a vaccine that can help protect against many of these HPV
infections.
However, this study of Costa Rican women, aged 18 to 97, concluded that
the benefits of HPV vaccination and screening are low among women over
the age of 41. The rate of newly detected cancer-causing HPV infections
declined with age, ranging from 35 percent in women aged 18 to 25 to
13.5 percent in women aged 42 and older.
More info
Merck Sharpe and Dohme publishes positive Gardasil trial data
Posted on
18/02/2010 in Pharmaceutical Company Product News
Merck
Sharpe and Dohme has published new clinical trial data from a study of
its human papillomavirus (HPV) treatment Gardasil, which it believes
shows its efficacy for both males and females.
The
pharmaceutical company conducted a phase III trial to gauge the
effectiveness of the treatment in preventing infections and diseases
related to the sexually-transmitted condition.
More info
Merck s Study Show Gardasil Effective In anal diseases In Gays Update
2/17/2010
3:22 PM ET
(RTTNews)
- Wednesday, Merck & Co., Inc. (MRK: News ) said its
phase 3 trial of Gardasil was efficacious in preventing anal diseases
and anal cancer in gay men.
The
drug was found to be 77.5% efficacious against anal intraepithelial
neoplasia, associated with certain human papillomavirus or HPV types,
in 16-to-26 year-old men who have sex with men.
More info
Preliminary Data from Roche ATHENA Cervical Cancer Trial Support Value of Human Papillomavirus Genotyping
MONTE CARLO, Monaco, Feb. 18
/PRNewswire-FirstCall/ -- Roche Molecular Systems, Inc. (SIX: RO, ROG;
OTCQX: RHHBY) announced today that preliminary data from its ATHENA
(Addressing THE Need for Advanced HPV Diagnostics) trial support the
importance of screening for human papillomavirus (HPV) genotypes that
put women at highest risk for developing cervical cancer. ATHENA is a
prospective, double-blind, multi-centered, 47,000-patient,
U.S.-registration trial designed to demonstrate the effectiveness of
HPV detection as part of a cervical cancer screening program. Thomas C.
Wright Jr., M.D., of Columbia University presented the preliminary data
on February 18 during the Genotyping session (Scientific Session 2) at
the EUROGIN 2010 congress in Monaco.
"The findings to date
from the ATHENA trial support the growing understanding that certain
HPV genotypes are highly associated with the development of high-grade
cervical intraepithelial neoplasia (CIN grade 2 or higher), a direct
precursor to cervical cancer," said Dr. Wright.
Registros
1
a
10
de
51
Print
